---
layout: default
title: Avibactam Sodium
parent: 僅模型預測 (L5)
nav_order: 106
evidence_level: L5
indication_count: 0
---

# Avibactam Sodium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Avibactam Sodium: From Bacterial Infections – No Repurposing Prediction Available

## One-Sentence Summary

Avibactam Sodium is a non-beta-lactam beta-lactamase inhibitor, used in combination with ceftazidime (Ceftazidime-avibactam) for the treatment of serious gram-negative bacterial infections, including carbapenem-resistant organisms.
The TxGNN model has **not generated any predicted repurposing indications** for this drug in the current analysis run.
Due to multiple data gaps — including missing mechanism of action data, empty licence details, and absent safety information — this candidate **cannot proceed to full repurposing evaluation** at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Serious gram-negative bacterial infections (combination product with ceftazidime) |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 – Model prediction absent; no supporting studies identified |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was returned for Avibactam Sodium in the current evidence pack. As a result, there is no predicted new indication to evaluate for mechanistic plausibility.

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacological class, Avibactam Sodium is a diazabicyclooctane (DBO) beta-lactamase inhibitor administered exclusively in combination with ceftazidime. Its activity lies in protecting the co-administered beta-lactam antibiotic from enzymatic degradation by class A, class C, and some class D beta-lactamases — including KPC and OXA-48 — in resistant gram-negative pathogens such as *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*.

Given that the drug's pharmacological activity is inherently tied to a partner molecule (ceftazidime) and acts via an inhibitory mechanism rather than direct cytotoxic or receptor-mediated effect, any meaningful repurposing hypothesis would require the full combination to be evaluated. Until a TxGNN prediction is generated and regulatory/MOA data gaps are resolved, repurposing evaluation cannot be meaningfully conducted.

---

## Malaysia Market Information

One registration was identified in the Malaysian NPRA database. However, product-level details (product name, dosage form, manufacturer, and approved indication text) were not returned in the current data pull and require a supplementary query.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|-------------------|
| — | — | — | Details not returned in current data pull; supplementary NPRA query required |

---

## Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications, or drug–drug interaction data were available in this evidence pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate has no TxGNN repurposing prediction output and carries multiple blocking data gaps (missing MOA, empty licence details, absent safety data), making it impossible to conduct a meaningful repurposing evaluation or safety pre-screen at this stage.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction pipeline** to determine whether a repurposing candidate score exists for Avibactam Sodium; confirm whether the drug's DrugBank ID can be resolved (currently null) to enable knowledge-graph traversal
- **Resolve DrugBank ID** via DrugBank API lookup to unlock MOA data, drug category, and toxicity profile (Data Gap DG002)
- **Download and parse the NPRA/TFDA package insert PDF** to populate approved indication text, key warnings, and contraindications (Data Gap DG001)
- **Supplementary NPRA query** to retrieve complete product-level registration details (product name, dosage form, manufacturer)
- Once the above are resolved, re-generate the evidence pack and re-evaluate under the standard L1–L5 evidence framework

> ⚠️ *This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

